The 2025 American Academy of Dermatology (AAD) Annual Meeting introduces over 50 new sessions and debuts an opening ceremony, featuring a fireside chat with lifestyle expert and entrepreneur Martha Stewart.
This content was developed independently and is not endorsed by the American Academy of Dermatology.
Clinicians and investigators will gather in Orlando, Florida, for the 2025 American Academy of Dermatology (AAD) Annual Meeting from March 7 to 11 to explore challenges across the dermatology field, anticipate future developments, and connect with peers and industry leaders.
The 2025 American Academy of Dermatology (AAD) Annual Meeting introduces over 50 new sessions and debuts an opening ceremony, featuring a fireside chat with lifestyle expert and entrepreneur Martha Stewart. | Image Credit: Kevin Ruck - stock.adobe.com
The comprehensive program features over 300 sessions led by dermatology experts, organized into 6 categories: inflammatory dermatoses, pediatric dermatology, cosmetic dermatology, surgical dermatology, practice management, and melanoma and non-melanoma skin cancers.1
This array of sessions includes returning favorites from past meetings, like the late-breaking research sessions. These sessions will showcase new clinical trials, population-based studies, innovative technologies, translational biomarker research, and groundbreaking basic science.2
The featured research will cover various skin, hair, and nail disorders, focusing on discoveries that enhance the understanding of disease mechanisms, drive therapy development, or improve adverse event prevention. Two late-breaking research sessions will be held on Saturday, March 8, the first from 9 a.m. to 12 p.m. and the second from 1 p.m. to 4 p.m.
Another session back by popular demand is “Hot Topics,” which will take place on Monday, March 10, from 9 a.m. to 12 p.m.3 This symposium will cover dermatology topics deemed most relevant by registrant consensus, reflecting member interests and concerns. Expert speakers will discuss recent trends and developments in the field, especially highlighting emerging and innovative therapies.
There are also over 50 new sessions, including “New Drugs, New Rashes: An Update on Cutaneous Drug Eruptions.4” This session, taking place on Friday, March 7, from 1 p.m. to 3 p.m. will help dermatologists to stay updated on management strategies for adverse drug reactions, which have become more common with the use of newer medications, such as anti-cancer drugs and biologics, that cause distinctive and serious cutaneous effects.
Another new aspect of the meeting is the opening ceremony on Friday, March 7, at 5 PM.5 It will include a welcome address from AAD President Seemal R. Desai, MD, FAAD, to set the stage for the remainder of the meeting. Attendees will also hear remarks from this year’s Gold Medal winner, Boni E. Elewski, MD, FAAD, who is receiving AAD’s highest honor in recognition of her contributions to the specialty.
To conclude the opening session, Desai will host a fireside chat with lifestyle expert and entrepreneur Martha Stewart. They will explore her contributions to health care, her connections to dermatology, and her personal and professional journey.
In an interview with The American Journal of Managed Care®, Desai reflected on the goals of the 2025 AAD Annual Meeting. His message to members is that AAD is committed to providing them with the highest quality, cutting-edge education and various networking opportunities.
“When you come to our meeting, you’re coming to get the absolute best content anywhere in the world,” Desai said. “We want our members to know that we are making sure that they have the most exciting experience while they’re there because we know that it’s a time commitment, it’s a monetary commitment, and it’s an incredibly busy time for so many people. We want everyone to feel like, when they leave there, they received the best education and had the best networking experience.”
References
New Insights Into Meth-Associated PAH Care Gaps: Anjali Vaidya, MD, on Closing the Divide
June 4th 2025Research from Anjali Vaidya, MD, FACC, FASE, FACP, Temple University Hospital, reveals critical care gaps for patients with methamphetamine-associated pulmonary arterial hypertension (PAH), emphasizing the need for early diagnosis and integrated support.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL
June 3rd 2025Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Depth of Responses, PFS in Transplant-Ineligible Patients Match Overall Findings in CEPHEUS
June 2nd 2025Quadruplet therapy is now the accepted standard for patients newly diagnosed with myeloma who are ineligible for transplant; there is debate whether all newly diagnosed patients should have this regimen.
Read More
Trastuzumab Deruxtecan Plus Pertuzumab Improves PFS vs Standard Care in HER2+ Breast Cancer
June 2nd 2025Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free survival (PFS) in HER2-positive breast cancer, potentially representing a new standard of care.
Read More